Population Pharmacokinetics and Pharmacodynamics of Sitafloxacin in Plasma and Alveolar Epithelial Lining Fluid of Critically Ill Thai Patients With Pneumonia
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Taniya Paiboonvong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Rangsit University, Pathum Thani, Thailand. Hauptthemen laut MEDLINE: Fluoroquinolones, Anti-Bacterial Agents, Pneumonia. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was partially supported by Chiang Mai University.
Abstract (Originalsprache)
Sitafloxacin is one of the oral respiratory quinolones for the treatment of community‐acquired pneumonia. The pharmacokinetic (PK) changes of sitafloxacin in critical illness have been previously reported. However, sitafloxacin exposure and target attainment have never been confirmed in this population. To develop a population pharmacokinetic (PK) model of sitafloxacin, plasma and epithelial lining fluid (ELF) concentrations were obtained after sitafloxacin administration as a 200‐mg single dose under fasting condition in 12 subjects. A population pharmacokinetic analysis was performed using a nonlinear mixed‐effects modeling approach. The probability of target attainment (PTA) and cumulative fraction of response (CFR) against the MIC distribution of S. pneumoniae isolated from Thai patients was estimated by Monte Carlo simulations. The pharmacokinetics of sitafloxacin in plasma was best described by a one‐compartment model linking to the ELF compartment. The partition coefficient which relates drug exposure in ELF to drug exposure in plasma was estimated to be 0.77. Age was a significant covariate that impacted the relative bioavailability. Results from Monte Carlo simulations showed that the maximum approved dose of sitafloxacin 100 mg q 12 h provided > 90% PTA and CFR in both plasma and ELF. The current maximal dosing of sitafloxacin provided adequate exposure in plasma and ELF for the treatment of critically ill Thai patients with pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
- Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
- Department of Pharmaceutical Care, Faculty of Pharmacy, Payap University, Chiang Mai, Thailand.
- Division of Clinical Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.
- Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Taniya Paiboonvong, Preecha Montakantikul
Förderung
- This research was partially supported by Chiang Mai University
Zitieren
APA
Paiboonvong, T., Montakantikul, P., Panjasawatwong, N., Singkham, N., & Punyawudho, B. (2025). Population Pharmacokinetics and Pharmacodynamics of Sitafloxacin in Plasma and Alveolar Epithelial Lining Fluid of Critically Ill Thai Patients With Pneumonia. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70081
Vancouver
Paiboonvong T, Montakantikul P, Panjasawatwong N, Singkham N, Punyawudho B. Population Pharmacokinetics and Pharmacodynamics of Sitafloxacin in Plasma and Alveolar Epithelial Lining Fluid of Critically Ill Thai Patients With Pneumonia. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70081
BibTeX
@article{Paiboonvong2025,
author = {Paiboonvong, Taniya and Montakantikul, Preecha and Panjasawatwong, Navarat and Singkham, Noppaket and Punyawudho, Baralee},
title = {Population Pharmacokinetics and Pharmacodynamics of Sitafloxacin in Plasma and Alveolar Epithelial Lining Fluid of Critically Ill Thai Patients With Pneumonia},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70081}
}
EUVIMED